DANIELLE MEKAHEL: Open Payments
NPI 1205329000 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$719 in 35 payments from 7 companies in 2025. Trend: 2023 $303 · 2024 $1,024 · 2025 $719
Food & beverage: $719
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 12 | $204 |
| Novo Nordisk Inc | 7 | $147 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $96 |
| Amgen Inc. | 4 | $91 |
| Exeltis, USA Inc. | 4 | $89 |
| Lilly USA, LLC | 3 | $76 |
| MILLICENT US INC | 1 | $16 |
Products named: MYFEMBREE, Wegovy, XIFAXAN, SLYND, MOUNJARO, EVENITY, Saxenda, REPATHA.
Industry payments across CA — which companies pay providers there.
